## **Supplementary Materials**

## Rare Chromone Derivatives from the Marine-Derived *Penicillium citrinum* with Anti-Cancer and Anti-Inflammatory Activities

## Yi-Cheng Chu<sup>1</sup>, Chun-Hao Chang<sup>2</sup>, Hsiang-Ruei Liao<sup>3</sup>, Ming-Jen Cheng<sup>4</sup>, Ming-Der Wu<sup>4</sup>, Shu-Ling Fu<sup>1,\*</sup> and Jih-Jung Chen<sup>5,6,\*</sup>

- <sup>1</sup> Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan; xbox88888@ym.edu.tw (Y.-C.C.)
- <sup>2</sup> Institute of Biopharmaceutical Sciences, Pharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan; howard860212@ym.edu.tw (C.-H.C.)
- <sup>3</sup> Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan; liaoch@mail.cgu.edu.tw (H.-R.L.)
- <sup>4</sup> Bioresource Collection and Research Center (BCRC), Food Industry Research and Development Institute (FIRDI), Hsinchu 300, Taiwan; cmj@firdi.org.tw (M.-J.C.); wmd@firdi.org.tw (M.-D.W.)
- <sup>5</sup> Faculty of Pharmacy, School of Pharmaceutical Sciences, National Yang-Ming University, Taipei 112, Taiwan
- <sup>6</sup> Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404, Taiwan
  \* Correspondence: chenjj@ym.edu.tw (J.-J.C.); slfu@ym.edu.tw (S.-L.F.)
- Tel.: +886-2-2826-7195 (J.-J.C.); +886-2-2826-7177 (S.-L.F.) ; Fax: +886-2-2823-2940 (J.-J.C.); +886-2-2822-5044 (S.-L.F.)

## Contents

Figure S1. HRESIMS spectrum of 1	S4
Figure S2. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 500 MHz) of 1	S4
Figure S3. <sup>13</sup> C NMR spectrum (CDCl <sub>3</sub> , 125 MHz) of 1	S5
Figure S4. <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 1	S5
Figure S5. Expanded <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 1	S6
Figure S6. ROESY spectrum of 1	S6
Figure S7. Expanded ROESY spectrum of 1	S7
Figure S8. HMBC spectrum of 1	. S7
Figure S9. HSQC spectrum of 1	. S8
Figure S10. CD spectrum of 1	. S8
Figure S11. HRESIMS spectrum of 2	S9
Figure S12. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 500 MHz) of 2	S9
Figure S13. <sup>13</sup> C NMR spectrum (CDCl <sub>3</sub> , 125 MHz) of 2	S10
Figure S14. <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 2	S10
Figure S15. Expanded <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 2	S11
Figure S16. ROESY spectrum of 2	S11
Figure S17. Expanded ROESY spectrum of 2	S12
Figure S18. HMBC spectrum of 2	. S12
Figure S19. HSQC spectrum of 2	. S13
Figure S20. CD spectrum of 2	S13
Figure S21. HRESIMS spectrum of 3	S14
Figure S22. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 500 MHz) of 3	S14
Figure S23. <sup>13</sup> C NMR spectrum (CDCl <sub>3</sub> , 125 MHz) of 3	S15
Figure S24. <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 3	S15
Figure S25. Expanded <sup>1</sup> H- <sup>1</sup> H COSY spectrum of 3	S16
Figure S26. ROESY spectrum of 3	S16
Figure S27. Expanded ROESY spectrum of 3	S17

Figure S28. HMBC spectrum of 3	S17
Figure S29. HSQC spectrum of 3	S18
Figure S30. CD spectrum of 3	S18
Figure S31. HRESIMS spectrum of 4	S19
Figure S32. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 500 MHz) of 4	S19
Figure S33. <sup>13</sup> C NMR spectrum (CDCl <sub>3</sub> , 125 MHz) of 4	S20
Figure S34. CD spectrum of 4	S20
Figure S35. HRESIMS spectrum of 5	S21
Figure S36. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 600 MHz) of 5	S21
Figure S37. HRESIMS spectrum of 6	S22
Figure S38. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 600 MHz) of 6	S22
Figure S39. HRESIMS spectrum of 7	
Figure S40. <sup>1</sup> H NMR spectrum (CDCl <sub>3</sub> , 600 MHz) of 7	S23
Figure S41. CD and ECD spectra of epiremisporine B	S24
Table S1. 1H NMR spectrum of 4 and epiremisporine B	S24
Table S2. <sup>13</sup> C NMR spectrum of 4 and epiremisporine B	S25
Table S3. The ROESY correlations for compounds 1–3	S26



Figure S1. HRESIMS spectrum of 1.



Figure S2. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of 1.



Figure S3. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) spectrum of 1.



Figure S4. <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 1.



Figure S6. ROESY spectrum of 1.



Figure S7. Expanded ROESY spectrum of 1.



Figure S8. HMBC spectrum of 1.



Figure S9. HSQC spectrum of 1.



Figure S10. CD spectrum of 1.



Figure S11. HRESIMS spectrum of 2.



Figure S12. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of 2.





Figure S14. <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 2.



Figure S15. Expanded <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 2.





Figure S17. Expanded ROESY spectrum of 2.







Figure S20. CD spectrum of 2.



Figure S21. HRESIMS spectrum of 3.



Figure S22. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of 3.



Figure S23. <sup>13</sup>C NMR spectrum of 3 (CDCl<sub>3</sub>, 125 MHz) of 3.



Figure S24. <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 3.



Figure S25. Expanded <sup>1</sup>H–<sup>1</sup>H COSY spectrum of 3.





Figure S27. Expanded ROESY spectrum of 3.





Figure S29. HSQC spectrum of 3.



Figure S30. CD spectrum of 3.



Figure S31. HRESIMS spectrum of 4



Figure S32. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 500 MHz) of 4.



Figure S33. <sup>13</sup>C NMR spectrum (CDCl<sub>3</sub>, 125 MHz) of 4.



Figure S34. CD spectrum of 4.



Figure S35. HRESIMS spectrum of 5.



Figure S36. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 600 MHz) of 5.



Figure S37. HRESIMS spectrum of 6.



Figure S38. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 600 MHz) of 6.



Figure S39. HRESIMS spectrum of 7.



Figure S40. <sup>1</sup>H NMR spectrum (CDCl<sub>3</sub>, 600 MHz) of 7.



Figure S41. CD and ECD spectra of epiremisporine B.

n '4'	4 (2'S) ª	4 (2' <i>R</i> ) ª	epiremisporine B (2'S) <sup>b</sup>	epiremisporine B (2'R) b		
Position	δ <sub>H</sub> (J in Hz)					
3	3.92 (t, 9.0)	3.88 (dd, 9.0, 8.3)	3.78 (dd, 9.2, 9.0)	3.88 (dd, 9.0, 8.4)		
4	5.19 (d, 9.0)	5.21 (d, 9.0)	4.98 (d, 9.0)	5.02 (d, 9.0)		
8	6.68 (br s)	6.69 (br s)	6.79 (s)	6.77 (s)		
10	6.60 (br s)	6.61 (br s)	6.64 (s)	6.64 (s)		
15	2.33 (s)	2.33 (s)	2.30 (s)	2.28 (s)		
16	3.79 (s)	3.83 (s)	3.69 (s)	3.70 (s)		
3′	3.02 (ddd, 11.7, 9.0, 5.9)	2.92 (ddd, 12.7, 8.3, 5.4)	3.10 (ddd, 10.1, 9.2, 6.4)	2.79(ddd, 12.5, 8.4, 5.9)		
$4'\alpha$	2.87 (dd, 16.8, 5.9)	2.82 (dd, 16.0, 5.4)	2.70 (dd, 17.0, 6.4)	2.48 (dd, 15.9, 5.9)		
4′β	2.62 (dd, 16.8, 11.7)	2.46 (dd, 16.0, 12.7)	2.64 (dd, 17.0, 10.1)	2.43 (dd, 15.9, 12.4)		
8'	6.71 (br s)	6.70 (br s)	6.90 (s)	6.88 (s)		
10'	6.70 (br s)	6.70 (br s)	6.71 (s)	6.71 (s)		
15′	2.42 (s)	2.42 (s)	2.38 (s)	2.38 (s)		
16′	3.88 (s)	3.86 (s)	3.74 (s)	3.75 (s)		
11-OH	12.04 (s)	12.00 (s)	12.15 (s)	12.12 (s)		
2'-OH	4.65 (br s)	4.41 (br s)	7.80 (s)	7.53 (s)		
11'-OH	12.34 (s)	12.29 (s)	12.49 (s)	12.47 (s)		

Table S1. <sup>1</sup>H NMR spectrum of 4 and epiremisporine B.

<sup>a</sup> Recorded in CDCl<sub>3</sub> at 500 MHz.

<sup>b</sup> Recorded in DMSO-d<sub>6</sub> at 600 MHz.

Position	4 (2'S) ª	4 (2' <i>R</i> ) <sup>a</sup>	epiremisporine B (2'S) •	epiremisporine B (2'R) <sup>b</sup>
1 05111011			δc, Type	
1	171.0, C	172.3, C	170.8, C	171.3, C
2	88.7, C	90.7, C	88.2, C	89.5, C
3	48.3, CH	48.2, CH	47.0, CH	46.6, CH
4	37.1, CH	36.4, CH	36.9, CH	36.2, CH
5	168.8, C	168.6, C	169.3, C	168.9, C
7	157.3, C	157.2, C	156.8, C	156.8, C
8	108.3, CH	108.3, CH	108.3, CH	108.3, CH
9	147.3, C	147.5, C	147.5, C	147.5, C
10	113.1, CH	113.2, CH	112.3, CH	112.3, CH
11	160.4, C	160.8, C	159.9, C	159.9, C
12	108.9, C	108.9, C	108.4, C	108.4, C
13	179.1, C	179.0, C	178.9, C	178.9, C
14	119.2, C	118.5, C	119.2, C	118.7, C
15	22.2, CH <sub>3</sub>	22.2, CH <sub>3</sub>	21.5, CH <sub>3</sub>	21.4, CH <sub>3</sub>
16	53.2, CH₃	53.6, CH <sub>3</sub>	52.8, CH <sub>3</sub>	52.6, CH <sub>3</sub>
1′	169.4, C	167.3, C	169.4, C	167.7, C
2′	104.8, C	105.9, C	105.7, C	106.2, C
3′	43.4, CH	47.1, CH	42.7, CH	47.3, CH
4′	26.3, CH <sub>2</sub>	27.5, CH <sub>2</sub>	26.3, CH <sub>2</sub>	26.9, CH <sub>2</sub>
5′	166.7, C	166.0, C	168.0, C	167.4, C
7′	156.1, C	156.1, C	155.5, C	155.6, C
8′	107.6, CH	107.6, CH	107.6, CH	107.6, CH
9′	147.5, C	147.7, C	147.4, C	147.4, C
10′	112.6, CH	112.6, CH	112.0, CH	112.0, CH
11′	160.4, C	160.8, C	159.5, C	159.6, C
12′	108.4, C	108.5, C	107.7, C	107.8, C
13′	179.8, C	179.7, C	179.4, C	179.3, C
14'	112.6, C	112.4, C	111.9, C	111.7, C
15′	22.4, CH <sub>3</sub>	22.4, CH <sub>3</sub>	21.8, CH <sub>3</sub>	21.8, CH <sub>3</sub>
16′	53.3, CH <sub>3</sub>	53.1, CH <sub>3</sub>	52.3, CH <sub>3</sub>	52.3, CH <sub>3</sub>

Table S2. <sup>13</sup>C NMR spectrum of 4 and epiremisporine B.

<sup>a</sup> Recorded in CDCl<sub>3</sub> at 125 MHz. <sup>b</sup> Recorded in DMSO-*d*<sub>6</sub> at 150 MHz.

	<b>1</b> a	<b>2</b> <sup>a</sup> ,	<b>3</b> a,
Position		ROESY	
3	4, 16, 3', 4'α	4, 16, 3', 4'α	4, 16, 3', 4'α
4	3	3	3
8	15	15	15
10	15	15, 11-OMe	15, 11-OMe
15	8, 10	8, 10	8, 10
16	3	3	3
3′	3, 4'α, 4'β, 2'-OMe	3, 4'α, 4'β, 2'-OMe	3, 4'α, 4'β
$4'\alpha$	3, 3', 4'β	3, 3', 4'β	3, 3′, 4′β
4'β	3', 4'α	3', 4'α	3', 4'α, 2'-OMe
8'	15′	15′	15′
10′	15′	15′	11'-OH, 15'
15'	8', 10'	8', 10'	8', 10'
11-OMe		10	10
2'-OMe	3′	3'	4'β
11'-OH			10'

Table S3. The ROESY correlations for compounds 1–3.

<sup>a</sup> Recorded in CDCl<sub>3</sub> at 500 MHz.